Clarivate Plc Stock Price, News & Analysis

Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, has announced it will release its third quarter 2024 financial results on Wednesday, November 6, 2024, before the market opens. The company will also host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.

Investors and interested parties can access the press release, earnings supplement, and accompanying financial information on the Clarivate investor website at https://ir.clarivate.com. The webcast will be open to all interested parties and may include forward-looking information.

Clarivate Plc (NYSE:CLVT) has announced the success of its annual Citation Laureates™ program, accurately predicting eight Nobel Prize 2024 recipients. The program, powered by the Web of Science Core Collection™ citation index, combines citation analysis with expert insights to identify potential Nobel laureates. Since 2002, 83 out of 441 Citation Laureates have received a Nobel Prize, with successful forecasts every year since 2007.

Notable predictions include David Baker, Demis Hassabis, and John M. Jumper for the Nobel in Chemistry, Victor Ambros and Gary Ruvkun for Physiology or Medicine, and Daron Acemoglu, Simon Johnson, and James A. Robinson for Economic Sciences. The success of the program highlights the value of Clarivate's data-driven approach in identifying researchers with exceptional citation records and potential Nobel honors.

Clarivate and Abiquifi have announced the agenda for the 2nd annual Summit LATAM, scheduled for October 7, 2024, in Milan. The event, preceding CPHI Milan, will focus on AI, data, strategic partnerships, and innovation opportunities in the Latin American pharmaceutical market, valued at $98 billion with projected growth of 10.1%.

Key sessions will cover topics such as driving growth with data and AI, competitive partnerships, regulatory guidelines, and local API production. The summit aims to address challenges and uncover opportunities in the region's evolving pharmaceutical landscape. Industry leaders from Clarivate, Abiquifi, Knight Therapeutics, EMS, Gene Pharm, Libbs Farmacêutica, ANVISA, Nortec, Emcure Mexico, and Globe Química will share insights and perspectives.

Clarivate Plc (NYSE:CLVT) has unveiled a comprehensive framework for evaluating the societal impact of research. The approach, detailed in a new report by the Institute for Scientific Information (ISI)™, addresses the growing demand for demonstrating the benefits of R&D investments across various sectors of society.

The framework categorizes societal needs into eight facets: Political & Policy, Legal & Governance, Economic, Human Capital, Medical, Social & Cultural, Technological and Environmental. It aims to balance qualitative and quantitative approaches, extending beyond traditional quantitative indicators.

To address the challenge of long timeframes between research discovery and societal application, the framework incorporates both lagging and leading indicators. This new approach will be integrated into the upcoming Web of Science Research Intelligence™ platform.

Clarivate Plc (NYSE: CLVT) has released a new report titled 'Excellence in IP Operations' based on a global survey of 184 IP professionals. The report highlights key challenges and trends shaping intellectual property (IP) operations, focusing on strategy alignment, resource allocation, technology enablement, and AI adoption.

Key findings include:

• 65% of corporate respondents with clear KPIs reported alignment between IP and business strategies
• Well-managed operational processes correlate with greater strategic alignment and efficient staff use
• 83% of respondents spending over half their time on unrelated tasks were not using AI in their IP department
• 64% of respondents dissatisfied with their technology setup spent more time on tasks outside their primary role

The report emphasizes the importance of aligning KPIs with business goals, effective process management, closing the AI adoption gap, and leveraging technology for efficiency in IP operations.

Clarivate Plc (NYSE: CLVT) has announced a strategic partnership with Relatable Healthcare to enhance medtech sales contracting processes. This collaboration integrates Clarivate's comprehensive competitive intelligence into Relatable's Product Relationship Management (PRM) platform, providing medtech companies with a single source of truth for product information and competitive data.

The partnership aims to empower clients to make informed pricing decisions, streamline sales contracting, and improve contract compliance. It addresses the challenges faced by medical device and supply companies in communicating product value and offering consultative insights in a cost-constrained healthcare environment.

By combining Clarivate's deep product-level market knowledge with Relatable Healthcare's enterprise software, the partnership equips medtech companies with tools to win new business and drive contract compliance more efficiently, particularly when serving Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), and various healthcare providers.

Clarivate Plc (NYSE:CLVT) has unveiled its Citation Laureates™ 2024 list, recognizing 22 exceptional scientists and economists from six countries whose work is considered of Nobel stature. These individuals have made significant contributions in areas such as clean energy, nanotechnology, 3D protein structures, and quantum computing. The list includes 11 researchers from the US, six from the UK, two from Switzerland, and one each from Germany, Israel, and Japan.

Clarivate's Institute for Scientific Information (ISI)™ has successfully identified 75 Citation Laureates prior to their Nobel success. The selection process is based on publication and citation data from the Web of Science™, focusing on authors whose papers have been cited more than 2,000 times. This year's laureates span fields including Physiology or Medicine, Physics, Chemistry, and Economics.

Clarivate Plc (NYSE:CLVT) has announced the full agenda for the 15th annual Clarivate Pharmavision India conference, scheduled for September 25-26, 2024, in Ahmedabad and Hyderabad. The event focuses on improving patient outcomes and building resilience in the healthcare ecosystem. Key topics include AI in healthcare, cell and gene therapy, and market access.

The conference aims to address challenges such as healthcare affordability and access in India. Industry leaders will discuss strategies for patient-centric innovation, R&D, generics, biosimilars, and healthcare manufacturing. Notable sessions will cover topics like balancing generics and innovation, AI's role in healthcare, and addressing barriers to cell and gene therapy integration in India.

Clarivate Plc (NYSE:CLVT) has launched Primo™ Research Assistant, a generative AI-powered library discovery solution. Developed in collaboration with library partners, it offers students and researchers a seamless experience with natural language queries and immediate answers grounded in trusted sources. Key features include:

• Semantic search and natural language queries
• AI-powered answers with source references
• Search suggestions for topic expansion
• Multi-language support

The solution is built on a Retrieval Augmented Generation (RAG) architecture and utilizes the Ex Libris Central Discovery Index (CDI), containing over 5 billion records. The beta program, which began in June 2024, involved 18 institutions across 10 countries. Clarivate aims to responsibly apply AI in academia, fostering trust and innovation in research.